MarketPulse

AACR Annual Meeting 2026

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Boundless Bio

Boundless Bio Touts First-in-Class Breast Cancer Drug as AACR Data Bolsters Rare DNA Target

Boundless Bio presented preclinical data for BBI-940, an oral kinesin degrader targeting extrachromosomal DNA in breast cancer, with Phase 1 trials underway.
BOLDbreast cancerPhase 1 clinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Unveils Novel Cancer Therapy Data Ahead of AACR 2026 Meeting

HUTCHMED to present preclinical data on first-in-class PI3K/PIKK therapy and updated Phase Ib/II surufatinib combination trial results at AACR Annual Meeting 2026.
HCMoncologycancer therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Cardiff Oncology's Onvansertib Shows Promise in Overcoming HER2-Low Breast Cancer Resistance

Cardiff Oncology's onvansertib shows preclinical promise in reversing HER2-low breast cancer resistance when combined with trastuzumab deruxtecan; data presentation scheduled for April 2026.
CRDFmetastatic colorectal cancerAACR Annual Meeting 2026
GlobeNewswire Inc.GlobeNewswire Inc.··Greenwich Lifesciences, Inc.

Greenwich LifeSciences Presents FLAMINGO-01 Trial Data at AACR 2026 Conference

Greenwich LifeSciences presents FLAMINGO-01 Phase III trial data at AACR 2026, showing 80% recurrence reduction. Non-HLA-A*02 arm fully enrolled with 250 patients.
GLSIbreast cancerGLSI-100